|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
M&A and ad-hoc company news was the primary driver of price action.
London, Paris and Southern Europe gained while Frankfurt slid Thursday.
An IPO of Shire's neuroscience division could also be on the cards.
Benchmarks saw a resoundingly positive session Wednesday.
The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.
Commodity markets, economic growth and the potential for a broad tightening of monetary policy in the developed world over the coming quarters recaptured investors' attention Thursday.
European stocks were mixed at the close of Wednesday's session ahead of a key date for both the U.K. and eurozone.
European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.
European stocks rebounded Friday as investors shook off the pessimism of recent days, with price action supported by both M&A as well as corporate earnings news.
Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.
Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home
Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...
Benchmarks were higher on Tuesday following strong gains among commodity, consumer and airline stocks
Pharmaceutical giant Allergan looks poised to have a great year in 2017.
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this...
The restaurants and the biotechs tried their best to save us but it just wasn't enough, Cramer says.
AbbVie's buyout of Shire reduces taxes but also grows its drug pipeline and adds cash flow.
European markets followed New York and Asia down this morning as investors were spooked by the shooting down of a Malaysian Airlines plane over Eastern Ukraine.
The Rosen Law Firm announces that it is investigating potential securities fraud claims against ShangPharma Corporation (NYSE: SHP) pertaining to allegations that ShangPharma issued a misleading and inadequate proxy...
ShangPharma (NYSE:SHP) has been downgraded by TheStreet Ratings from from a hold to sell.
Gentium, Concord Medical and ShangPharma are stocks that could deliver up to 72% as per consensus estimates.
These stocks are likely to outperform their peers, based on analysts' 12-month price targets.
These five firms could return 16% to 25% over the next 12 months based on analysts' consensus estimates.
ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced the appointment of William Dai...
ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or “the Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will be meeting ...
ShangPharma Corporation (NYSE:SHP) (“ShangPharma” or the “Company”), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that Kevin...
ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.